First Case of Severe, Life-Threatening Mpox Disease Reported in Major City

The first case of severe mpox (clade I) has been identified in New York City, health officials announced this week. The infected resident recently returned from international travel, marking a concerning development in the city’s public health landscape.

Unlike the less severe clade II variant that caused the 2022 global outbreak, clade I is known to cause more serious illness and potentially life-threatening complications. This strain has been responsible for the 2024 outbreak in the Democratic Republic of Congo and other parts of Africa, where it has resulted in higher mortality rates.

“Clade I causes more severe symptoms and can be life-threatening,” explained Dr. Marc Siegel, Fox News senior medical analyst. “It spreads via direct contact or sex, and kissing, and very close respiratory droplets, but not over longer distances by respiratory spread.”

Despite the concerning nature of this case, health officials are reassuring residents that the risk to the general public remains low. According to NYC Health Commissioner Dr. Alister Martin, there is no evidence of local transmission of mpox clade I in the city.

“This appears to have come here from travel and has not spread locally,” noted Dr. Siegel, emphasizing that this isolated case has not yet triggered community spread.

The virus typically manifests as a painful, blistery rash on various parts of the body, accompanied by fever, chills, exhaustion, muscle aches, headache, swollen lymph nodes, and respiratory symptoms. These symptoms usually appear one to three weeks after exposure. In severe cases, particularly with clade I infections, patients may develop eye infections, extensive rashes, debilitating skin lesions, and neurological complications.

Public health officials are recommending preventive measures for those at highest risk. The Centers for Disease Control and Prevention (CDC) specifically advises vaccination for men who are gay, bisexual, or have sex with men, are at least 18 years old, and have specific risk factors. The recommendation extends to travelers planning to visit regions where clade I mpox is actively spreading.

The JYNNEOS vaccine, administered in two doses, is the primary preventive measure available. This vaccine can both reduce the likelihood of infection and mitigate symptom severity if infection occurs. Close contacts of infected individuals should receive the vaccine within 14 days of exposure for optimal protection.

Treatment options for mpox focus primarily on symptom management. However, in severe cases, healthcare providers may prescribe TPOXX (tecovirimat), an antiviral medication developed to combat viruses related to smallpox, including mpox.

Individuals most vulnerable to severe mpox infections include those with compromised immune systems and very young children. This follows the pattern seen with many viral infections, where these populations tend to experience more serious complications.

This case emerges as global health organizations have been monitoring the spread of clade I mpox in Africa with increasing concern. The World Health Organization and various national health agencies have been coordinating response efforts to contain the outbreak and prevent its international spread.

While the identification of this case in New York City represents a significant development, health officials emphasize that the robust surveillance systems in place helped quickly identify the case, allowing for appropriate isolation and contact tracing measures.

The NYC Health Department continues to monitor the situation closely and urges at-risk individuals to complete the recommended two-dose vaccine series as a preventive measure. They also encourage healthcare providers to remain vigilant for potential cases, particularly among patients with recent travel history to affected regions.